Chip Hance

Robert (Chip) Hance is the former CEO of Creganna Medical, an Ireland-based medical device company with over 2,000 employees worldwide that was acquired by TE Connectivity in 2016.


In 2012-13, Chip was an Entrepreneur-in-Residence at the Center for Devices and Radiological Health within the United States Food and Drug Administration (FDA), where he co-led the Innovation Pathway team focused on streamlining aspects of medical device clinical trials in the U.S. Prior to his FDA experience, Chip was most recently President of Abbott Vascular, the cardiovascular device division of Abbott.


Over a decade in interventional cardiology at Abbott Vascular, he led the organization to global leadership in the drug-eluting stent market through the launch of Xience in the U.S., Japan and China. Chip also led the development and CE marking of Absorb, a bioabsorbable scaffold for the treatment of coronary disease and the acquisition and international expansion of Mitraclip, a percutaneous mitral valve repair device.


Chip earned a bachelor’s degree in Chemical Engineering from the Massachusetts Institute of Technology and a master’s degree in Business Administration from Harvard Business School.